<DOC>
	<DOCNO>NCT00383695</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving chemotherapy radiation therapy without cetuximab surgery may make tumor small reduce amount normal tissue need remove . It yet know whether give oxaliplatin , capecitabine , radiation therapy effective without cetuximab give surgery treat rectal cancer . PURPOSE : This randomized phase II trial study oxaliplatin , capecitabine , radiation therapy compare well work without cetuximab treat patient undergo surgery high-risk rectal cancer .</brief_summary>
	<brief_title>Oxaliplatin , Capecitabine , Radiation Therapy With Without Cetuximab Treating Patients Undergoing Surgery High-Risk Rectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare pathological complete response rate total mesorectal excision patient high-risk rectal cancer treat neoadjuvant therapy comprise oxaliplatin , capecitabine , radiotherapy without cetuximab . OUTLINE : This multicenter , open-label , randomize , control study . Patients stratify accord participate center presence T4 disease ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : - Neoadjuvant chemotherapy : Patients receive oxaliplatin IV 2 hour day 1 , 22 , 43 , 64 oral capecitabine twice daily day 1-14 , 22-35 , 43-56 , 64-77 . - Neoadjuvant chemoradiotherapy : Patients undergo radiotherapy daily day 85-89 , 92-96 , 99-103 , 106-110 , 113-117 , 120-124 receive oral capecitabine twice daily day 85-126 . - Surgery : Four six week completion chemoradiotherapy , patient undergo total mesorectal excision ( TME ) . - Adjuvant therapy : Beginning 6-8 week surgery , patient receive oxaliplatin IV 2 hour day 1 , 22 , 43 , 64 oral capecitabine twice daily day 1-14 , 22-35 , 43-56 , 64-77 . - Arm II : - Neoadjuvant therapy : Patients receive oxaliplatin capecitabine arm I neoadjuvant chemotherapy cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 . - Neoadjuvant chemoradiotherapy : Patients undergo radiotherapy receive capecitabine arm I neoadjuvant chemoradiotherapy cetuximab IV 1 hour day 85 , 92 , 99 , 106 , 113 , 120 . - Surgery : Four six week completion chemoradiotherapy patient undergo TME arm I . - Adjuvant therapy : Beginning 6-8 week surgery , patient receive oxaliplatin capecitabine arm I adjuvant chemotherapy cetuximab IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 . In arm , treatment continue absence disease progression unacceptable toxicity . Quality life assess periodically . After completion study treatment , patient follow every 3 month 1 year , every 6 month 2 year , annually 2 year . PROJECTED ACCRUAL : A total 164 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma undifferentiated nonsmall cell carcinoma rectum MRIdefined highrisk , operable disease , define ≥ 1 following : Tumors within 1 mm mesorectal fascia ( i.e. , circumferential resection margin threaten involve ) T3 tumor levator Tumors extend ≥ 5 mm perirectal fat T4 tumor Presence extramural venous invasion ( primary tumor therefore least T3 ) No evidence metastatic disease CT scan chest abdomen , require , positron emission tomography scan biopsy No rectal cancer unlikely operable even neoadjuvant treatment ( i.e. , tumor involve internal iliac vessel ) No T12 rectal cancer , absence highrisk factor T2 tumor within 1 mm mesorectal fascia allow No recurrent disease PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy &gt; 3 month WBC &gt; 3,000/mm³ Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Bilirubin &lt; 1.5 time upper limit normal ( ULN ) Transaminases &lt; 2.5 time ULN Creatinine normal OR creatinine clearance &gt; 50 mL/min Not pregnant nursing Fertile patient must use effective contraception No concurrent uncontrolled medical condition No active malignant disease within past 10 year except nonmelanoma skin cancer carcinoma situ cervix No contraindication MRI ( e.g. , pacemaker ) No medical psychiatric condition would preclude informed consent No know malabsorption syndrome lack physical integrity upper gastrointestinal tract No clinically significant ( i.e. , active ) cardiac disease , include follow : Congestive heart failure Symptomatic coronary artery disease Cardiac dysrhythmia ( e.g. , atrial fibrillation , even control medication ) Myocardial infarction within past 12 month No symptom history peripheral neuropathy PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy , investigational treatment rectal cancer No concurrent cytotoxic agent investigational drug No concurrent sorivudine sorivudine analogue ( e.g. , brivudine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
</DOC>